The current U.S. Presidential administration has indicated that it plans to pursue additional policies aimed at lowering prescription drug costs. For example, in April 2025, the President issued an executive order that, among other things, directs specified agency heads to:
(1) develop a Center for Medicare and Medicaid Innovation model that enables the Medicare program to obtain better value for high-cost prescription drugs and biological products;
(2) make it easier for States to import drugs from Canada; and
(3) issue recommendations to accelerate the approval of generics, biosimilars, combination products and second-in-class branded products. In May 2025, the President also issued an executive order directing the administration to take immediate steps to end global freeloading and take additional aggressive action should drug manufacturers fail to offer American consumers the most favored-nation (“MFN”) lowest price. In July 2025, the President sent letters to Gilead and other pharmaceutical manufacturers outlining the steps the President believes pharmaceutical manufacturers must take to bring down the prices of prescription drugs in the U.S. to match the MFN price offered in other developed nations. The specifics of these proposals and policies are unclear and, as a result, there is uncertainty as to how these and other potential legal and regulatory changes may impact our business.
All entries for: Gilead Sciences
Gilead Sciences - Foster City
Neutral Outlook
Foster City, CA
10,001-50,000 employees
Gilead Sciences - Oceanside
Layoffs
Oceanside, CA
10,001-50,000 employees
Gilead Sciences cut 36 employees in Oceanside, California, effective Aug. 15, according to a Worker Adjustment and Retraining Notification notice. The location supports clinical manufacturing and process development for the Foster City, California–based pharma and subsidiary Kite Pharma.
Gilead Sciences
Negative Outlook
Foster City, CA
10,001-50,000 employees
While the full impact of the IRA on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the IRA will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.
Gilead Sciences
Layoffs
Foster City, CA
10,001-50,000 employees
Gilead is trimming its California workforce by 149, according to a WARN Notice posted last week. The layoffs will take effect on May 27 and will affect scientific and technical services at the pharma’s site in Foster City.